Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis

Pfizer

Status: Completed

Conditions: Ankylosing Spondylitis

Treatments: Drug: Etanercept

Study type: Observational

Funder types: Industry

Identifiers

NCT04507763

B1801415

Details and patient eligibility

About

This study is to evaluate available data in Iraqi patients with ankylosing spondylitis on Enbrel treatment with regards to the impact of early treatment using data from the Baghdad Teaching Hospital registry

Enrollment: 763 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed AS patients.

  • 18 years old

• Did not receive previous biological treatment for any reason

Exclusion criteria

• Patients previously or currently treated with other biological therapies.
• Use of etanercept for less than 1 year duration.

Trial design

763 participants in 1 patient group

Patients with ankylosing spondylitis

Description:

Iraqi patients diagnosed with ankylosing spondylitis that received Etanercept as treatment for disease

Treatment:

Drug: Etanercept